Melanoma of the foot
Management of primary cutaneous melanoma of the hands and feet: a clinicoprognostic study. Rex J, Paradelo C, Mangas C, Hilari JM, Fernández-Figueras MT, Ferrándiz C. Dermatol...
Management of primary cutaneous melanoma of the hands and feet: a clinicoprognostic study. Rex J, Paradelo C, Mangas C, Hilari JM, Fernández-Figueras MT, Ferrándiz C. Dermatol...
WEDNESDAY, Oct. 28, 2026 — A personalized cancer vaccine can significantly improve survival odds for patients with advanced melanoma, a new clinical trial has found.Adding the vac...
The results of a landmark cancer vaccine trial demonstrate the power of treatments tailored to the person receiving them, hinting at a future where cancer treatments are personaliz...
A seventeen-year study of 400 patients finds that failure to visualise the sentinel lymph node on preoperative imaging in head and neck melanoma affects nearly one in eleven patien...
TUESDAY, Oct. 27, 2026 — Is that brown spot a sign of aging, or is it skin cancer?A new AI tool promises to help doctors suss out skin cancers, researchers reported Oct. 22 in the...
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Intratumoral co-administration of IL-12 and Flt3L mRNA lipid nanoparticles controlled anti-PD-1-refractory melanoma in mouse models by coordinating dendritic, natural killer, and T...
The Melanoma Research Foundation (MRF) will host its 25th Annual New York Gala on Thursday, October 15, at Guastavino's, marking a milestone celebration of the Gala's 25-year histo...
Children of parents who have melanoma, a serious type of skin cancer that starts in the cells that make pigment, have twice the lifetime risk of developing the disease themselves....
Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more.
A breakthrough treatment for the deadliest form of skin cancer can cut a patient’s risk of recurrence or death nearly in half. The new scientific revelation is powered by an mR...
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immu...
The international phase 3 trial involved 1137 people whose high-risk melanoma had been surgically removed.
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back.
Results from a phase III trial showed that a cancer vaccine can improve outcomes for certain patients with melanoma, highlighting the potential of personalized vaccines to reshape...
Mast cell tumours are the most familiar villain in canine dermatology, the single most common malignant skin cancer in dogs, accounting for an estimated 11 to 18 percent of all cut...
(CNN) — When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial...
A comprehensive scientific review synthesizes preclinical evidence revealing how m6A RNA modification governs melanoma progression, immune escape, and response to checkpoint immuno...
A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugma...
The personalized shots show significant promise for certain melanoma subtypes.
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.